Critical Advancements in Bioscience Make for Breakthrough Investment Opportunities

HOUSTON, TX / ACCESSWIRE / June 12, 2015 / Advancements in science have moved leaps and bounds ahead in
the past 50 years, and continue to grow at a break-neck pace. Creating more
efficient ways to examine, experiment, and catalog new studies is crucial to
developing new scientific methods, and making important, life-altering
discoveries. In the world of bioscience, this is especially true. Bioscience is
a huge scientific category that represents the process of studying biology, and
how to make improvements, correct errors, and find out the origins of
biological properties. This can include food science, botany, forensics,
genetics, human diseases and disorders, microbiology, and immunology to name
just a few.

But in order to successfully advance in the study of
bioscience, we must keep advancing and improving the technology to do so.
Because this need has been identified as critically important in recent years,
many companies have made it their mission to be the best, and most innovative
technology producers in their field. Needless to say, the industry is hot, and
only getting hotter.

Why investing in
Bioscience Technology is a no-brainer

Making the case for investment growth in bioscience
technology is simply a matter of looking at its demand. We live longer,
healthier, and safer thanks to advancements in bioscience, and none of it would
be possible without the proper tools and techniques. It’s a highly competitive
industry with nearly unlimited potential, which means picking the right company
to invest in is very important. With Pressure
Biosciences, Inc. (OTCQB: PBIO), we believe we’ve found a clear-cut
winner, and a phenomenal investment opportunity for long-term growth, and real
short-term gains. They refer to themselves as a “life science tools” company,
and are at the cutting edge of the latest applicable bioscience technology on
the market.

Pressure Biosciences,
Inc. is ahead of the curve

The key to success with PBIO is their patented, and market
tested technology that uses cycles of pressure to break, manipulate, and enhance
the examination of biological samples on a cellular and molecular level. Their patented, novel technology platform
is known as Pressure Cycling Technology (PCT), and PBIO is working vigorously
to help implement the PCT Platform into some of the world’s most advanced labs
and research facilities. This PCT process is unique, and has the potential to
change the bioscience industry as it is applied on a greater scale to an
already large and growing market.

Imagine being able to examine samples on a molecular level
with greater quality, reproducibility, and precision, as you manipulate the
samples using specific pressures to the exact size and shape you need them for
a study? This is what Pressure BioSciences, Inc. has patented with its PCT platform
technology, and so far, they’re the only ones in their field that are
successfully doing it. All they need now is a way to deliver this powerful technology
on a large scale to researchers worldwide, and with the proper investment,
they’re planning to do just that. To us, this is a no-brainer investment into
an industry with unlimited potential.

Who they are, in their
own terms

Pressure BioSciences,
Inc. (“PBI”) (PBIO) develops, markets, and sells proprietary
laboratory instrumentation and associated consumables to the estimated $6
billion life sciences sample preparation market. Their products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions.

What does PBIO have
in store for the future of bioscience, and bioscience technology?

To date, PBI has installed over 250 PCT systems in
approximately 160 sites worldwide. There are over 100 publications citing the
advantages of the PCT platform over competitive methods, many from key opinion
leaders. Their primary development and sales efforts are in the biomarker
discovery, drug discovery and design, and forensics areas. Customers also use
their products in other areas, such as bio-therapeutics characterization, soil
& plant biology, vaccine development, and counter-bioterror applications.

They are currently looking for investors to take the
company, and their unique PCT technology platform, to the next level. With the
systems and services they already have in place, they are positioned to be one
of the key players in the industry for the long haul. The market is there, and
isn’t going anywhere, and with technology as hot as PCT, the sky’s the limit
when it comes to applicability.

To learn more about investing in PBI, and to get an idea of
their stock and how it’s performing, check out their company
page on Interlinked.com

About FSXinterlinked and Interlinked: 

FSXinterlinked, the premier investment conference organization
founded in 1983 is a subsidiary of Interlinked, a global,
multi-dimensional investment platform that connects emerging-growth
companies with qualified funding sources by leveraging technology, media
and physical events to achieve its goals. Interlinked, along with its
two subsidiaries: InterlinkedTV, a media channel, and FSXinterlinked
have created an end to-end investment solution for an exclusive network
of companies and investors in the emerging-growth market. The
Interlinked investment platform enables its members to easily connect,
build relationships, and ultimately, close deals faster. For more
information, visit: http://www.interlinked.com or http://www.FSXinterlinked.com. 

Contact:

Delray Wannemacher
Interlinked
+1 719-641-7385
info@interlinked.com

SOURCE: Interlinked

ReleaseID: 429735